Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Apr. 30, 2018
Summary Of Significant Accounting Policies [Line Items]
Net sales	$ 406,562,000	$ 459,955,000	$ 453,042,000
Freezing amount in cash resulted from court pending legal action issued			2,600,000	$ 500,000
Advertising costs	900,000	800,000	600,000
Spinal Kinetics [Member]
Summary Of Significant Accounting Policies [Line Items]
In-process research and development costs					$ 26,800,000
Musculoskeletal Transplant Foundation ("MTF") [Member]
Summary Of Significant Accounting Policies [Line Items]
Expenditures for other research and development	800,000	0
Customers and Distributors Based in Europe [Member]
Summary Of Significant Accounting Policies [Line Items]
Net sales	57,700,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Transactional foreign currency gains and (losses), including those generated from intercompany operations	3,900,000	$ (1,400,000)	(3,300,000)
Maximum [Member] | Neo Medical SA [Member]
Summary Of Significant Accounting Policies [Line Items]
Expenditures for other research and development	$ 100,000
General and administrative [Member]
Summary Of Significant Accounting Policies [Line Items]
Decreases to general and administrative expenses			$ (1,300,000)